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Thiol groups tend to interact with metal
ions, particularly with heavy metal ions.
Consequently, cysteine (Cys) residues of pro-
teins are often involved in binding, transport,
and storage of metals in the cell, as well as in
detoxiﬁcation therapies (1,2). Among the 20
natural amino acids that constitute the build-
ing blocks of proteins, Cys is unique for at
least three reasons, connected with the pres-
ence of a thiol moiety in its molecule, which
confers special physicochemical properties to
its derivatives. First, two such moieties incor-
porated in two Cys residues, present in the
same protein or on different polypeptide
chains, easily participate in oxido-reduction
processes leading to the formation of disulﬁde
(S—S) bonds. These are critical for the
proper folding of many proteins (Scheme 1,
Reaction 1) (1,2). In vivo, this process
requires a sufﬁciently oxidizing environment
and at least two catalytic proteins, endoplas-
mic reticulum oxidoreductin 1 protein
(Ero1p) and protein disulfide isomerase,
whose roles in protein folding were only
recently investigated in some detail (1).
Furthermore, the thiol moiety of Cys residues
present in proteins may participate in other
oxido-reduction processes, involving other
oxidants present in the environment, such as
oxygen and oxygen radicals (superoxide, per-
oxide, hydroperoxide, etc.), thiol reagents,
glutathione (when a thiol/disulﬁde exchange
reaction of the type shown in Scheme 1,
Reaction 2), occurs or nitric oxide or some of
its precursors such as nitrous acid (when S-
nitrosothiols are formed; Scheme 1, Reaction
3), to mention only the most common ones
(1,2). In all these processes the –SH moiety
of the targeted Cys residue(s) is modified,
leading to drastically changed properties of
the corresponding protein, which may have
important physiological/pharmacological
consequences.
Second, the thiol moiety (in its
deprotonated, thiolate form—the pKa of –SH
in Cys is around 8.5 but may be lowered up
to 6 when this moiety is in the neighborhood
of other amino acid residues) easily partici-
pates in coordination of transition metal ions
(Mx+) important in physiological processes,
such as Zn(II), Cu(II), Fe(III), and so forth
(Scheme 1, Reaction 4) (2–4). A large num-
ber of metallo-enzymes incorporate Zn(II) or
Cu(II) ions coordinated by one or several
–SH groups belonging to Cys residues [e.g.,
DNA and RNA polymerases, aspartate tran-
scarbamoylase, ornithine decarboxylase, alco-
hol dehydrogenase, carbonic anhydrase,
various proteases, endoglucanase, β -lactamase
II, etc. (3,4)], whereas the metallothioneins—
proteins that contain around 60 amino acid
residues, 20 of which are Cys, bind up to
seven Zn(II) ions (and also copper, cadmium,
iron, or other trace elements), playing impor-
tant biological functions correlated with the
transport and availability of zinc (and other
metal) ions in organisms such as higher verte-
brates (2–4). The metallothioneins are also
involved in the acute intoxication with metal
ions such as cadmium, copper, lead, and
nickel (4). Furthermore, the zinc ﬁnger pro-
teins in which a Zn(II) ion is coordinated by
Cys and His residues constitute a large super-
family of nucleic acid binding proteins that
are also one of the major subsets of transcrip-
tion factors in viruses, prokaryotes, and
eukaryotes (4).
Third, the –SH group of Cys, similarly to
many other thiol moieties, has a strongly
nucleophilic character (mainly in the thiolate
form), which allows its easy derivatization by
many electrophiles (E+), such as haloacetates,
maleimides, activated sulfonyl groups, etc. In
all these cases, a modified Cys residue is
obtained, which possesses completely different
physicochemical properties (Scheme 1,
Reaction 5) (5). The S-alkylation/arylation, S-
acylation, or S-sulfonylation of Cys residues,
caused by the last property mentioned above,
is indeed of exceptional importance mainly for
the design of novel anticancer therapies (2,5).
In this article, we review the many
therapeutic applications that recently have
been developed, considering the three above-
mentioned properties of the Cys residues
(i.e., their participation in oxido-reduction
processes, their metal ion–coordinating prop-
erties, and their nucleophilicity and propensity
to be alkylated/acylated or modiﬁed by means
of other reagents). Such applications mainly
deal with the design of novel antivirals and
some new anticancer therapeutic approaches.
Antivirals
Anti-HIV Agents
Human immunodeficiency virus (HIV)
infection affects more than 36 million
people worldwide (2,6). Although much
progress has been made in the treatment of
HIV infection by the introduction of highly
active antiretroviral therapy (HAART; a
combination of nucleoside and nonnucleo-
side reverse transcriptase inhibitors, and/or
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Modiﬁcation of cysteine residues in proteins, due to a) the participation of the thiol moiety of this
amino acid in oxido-reduction reactions, b) its ability to strongly coordinate transition metal ions,
or c) its nucleophilic nature and facile reaction with electrophiles, may be critically important for
the design of novel types of pharmacological agents. Application of such procedures recently led to
the design of novel antivirals, mainly based on the reaction of zinc ﬁnger proteins with disulﬁdes
and related derivatives. This approach was particularly successful for developing novel antiviral
agents for human immunodeficiency virus and human papilloma virus. Several new anticancer
therapeutic approaches, mainly targeting tubulin, have also been reported. Thus, this unique
amino acid offers very interesting possibilities for developing particularly useful pharmacological
agents, which generally possess a completely different mechanism of action compared with classic
agents in clinical use, thus avoiding major problems such as multidrug resistance (for antiviral and
anticancer agents) or high toxicity. Key words: anticancer agent, antiviral agent, cysteine, thiol.
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aspartic protease inhibitors), the massive
viral replication (with >109 virions produced
daily) and the high error rate of the reverse
transcriptase lead to the emergence of drug-
resistant strains and the urgent need for new
therapeutic approaches (6).
A new target for the development of
anti-HIV therapies has been reported by
Rice et al. to be the HIV-1 nucleocapsid
(NC) zinc finger protein NCp7 (7). All
retroviruses (except spumaretroviruses) con-
tain in their NC proteins one or two copies
of a conserved sequence motif termed the
Cys array or the Cys–His box, composed the
sequence C–(X)2–C–[X]4–H–[X]4–C (C =
cysteine, H = histidine, X = any amino acid;
the number after the brackets is the number
of amino acid residues between the two ele-
ments mentioned above) (7–10). This motif
is also known as the NC zinc ﬁnger because
a Zn(II) ion is tetrahedrally coordinated by
the thiolate of the three Cys residues and the
imidazole nitrogen belonging to the histi-
dine residue (7–10). The NC proteins of all
retroviruses are indeed essential for the viral
life cycle because they select viral RNA from
cellular RNA for dimerization and packag-
ing, promote binding of the essential trans-
fer RNA primer to the primer site, stimulate
reverse transcription, and protect the viral
RNA from nucleases, and their mutation/
modiﬁcation is not tolerated (7–10). Rice et
al. (7–10) showed that it is possible to target
NCp7 by chemically modifying the nucle-
ophilic sulfur atoms coordinating the Zn(II)
ions in the above-mentioned zinc fingers,
with 3-nitrosobenzamide derivatives 1, disul-
fide benzamides 2, dithianes 3, or azodicar-
bonamide 4, among others, the process being
followed by zinc extrusion from the zinc ﬁn-
ger and production of noninfective virions.
Furthermore, no resistance to such agents
has been observed (7–10) because, as stated
above, no mutations in the NC proteins are
tolerated by retroviruses, HIV included.
The mechanism of action of such zinc
ﬁnger–targeting agents of types 1–4 has been
investigated in detail (7–10): the zinc is
ejected in a stoichiometric, oxidative manner.
Initially, the antiviral agent (i.e., a dithio-
bisamide 2) forms an intermolecular disulﬁde
bond (by means of a disulﬁde exchange reac-
tion; Scheme 1, Reaction 2) because of an
electrophilic attack on one of the sulfur atoms
coordinating the Zn(II) of the zinc finger.
This process leads to the destabilization of the
Zn(II) ion coordination sphere and is fol-
lowed by ejection of the metal ion from the
zinc finger. The initial process may then be
followed by the formation of intramolecular
disulﬁdes within the protein as well as disul-
ﬁde bond rearrangements, but regardless, the
final result is the denaturation of the zinc
finger protein, which is lethal for the virus,
leading to the formation of noninfective viri-
ons (7–10). It should be stressed that these
compounds do not act as competitors per se
for binding of zinc ions other than those
belonging to zinc ﬁnger proteins. Some of the
most active of such derivatives are shown in
Table 1, together with second-generation
compounds, belonging to the pyridinioalka-
noyl thiolester type of derivative 5 in Table 1.
Among the most effective antiviral derivatives
are some sulfonamides (2a, 2c, and 5a in
Table 1).
It has also been proven that some of
these agents (2 and 5 in Table 1) possess
selectivity for the viral zinc finger protein
(NCp7), without appreciably reacting with
several cellular zinc fingers, such as the
poly(ADP-ribose) polymerase and the Sp1
and GATA-1 transcription factors, nor did
they inhibit HeLa nuclear extract–mediated
transcription (10). This finding is of great
importance in validating these compounds
as valuable leads for the development of new
antiviral drugs.
Antihuman Papilloma Virus Agents
Among the DNA viruses provoking
debilitating disease responsible for signiﬁcant
mortality and morbidity, human papilloma
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Table 1. Antiviral activity of compounds targeting NCp7.
Structure
Type RNH EC50 (µM)a IC50 (µM)a Zinc ﬁnger reactivity Structure
2a 4-NHC6H4–SO2NH2 0.85 217 Medium
2b 4-NHC6H4–SO2NHAc 1.5 > 200 Medium
2c 4-NHCH2C6H4–SO2NH2 1.4 30 Medium
2d 4-NHC6H5 3.7 7 –
2e –NH-i-Bu 1.8 4.6 Medium
2f –NH-β -Ala 7.8 > 120 High
2g –NH-Val 5.0 140 High
5a 4-NHCH2C6H4–SO2NH2 1.1 55 1.4
5b 4-NHC6H4–SO2NHAc 6.2 > 316 3.6
5c 4-NHC6H4–SO2C6H4-4-NO2 5.5 > 316 4.1
aAntiviral activity was measured, by the XTT cytoprotection assay, as described elsewhere (7–10). EC50 represents the molarity of compound that provides 50% cytoprotection (prevention
of HIV-induced cytopathicity), whereas IC50 represents the molarity of compound eliciting 50% cell death and is a measure of the toxicity of these derivatives.
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viruses (HPVs) represent a special case. HPVs
provoke different forms of benign and malig-
nant mucocutaneous disease (common warts,
plantar and palmar warts, genital warts, epider-
modysplasia verruciformis) (11), and some of
these viruses, such as HPV-16 and HPV-18,
are also associated with cervical cancer, a par-
ticularly serious form of cancer (approximately
a half million women worldwide die of this
disease every year) (11). Currently, therapeutic
options for HPV infections are limited, expen-
sive, and ineffective (11), and they include
surgery or immune modulators, such as inter-
feron (11) and imiquimod (2).
Three proteins associated with oncogene-
sis promoted by HPV-16 have been isolated:
E5, E6, and E7 (12). E6 and probably also E7
play an important role in crucial biochemi-
cal/cellular processes, such as transmembrane
signaling, regulation of cell cycle, transforma-
tion of established cell lines, and ultimately
oncogenesis (12). The E6 oncoprotein of
HPV-16 contains 158 amino acid residues
and incorporates two Cys–[X]2–Cys–[X]29–
Cys–[X]2–Cys zinc ﬁngers (12). The structure
and function of this oncoprotein are strongly
dependent on these zinc ﬁngers, which assure
integrity and stability because of chelation of
the metal ion by the four –SH moieties of
the Cys residues mentioned above (12).
Taking into account the successful design of
zinc finger oxidants targeted against HIV-1
previously described, it was logical to extend
this approach to other interesting viral pro-
teins, such as E6. Beerheide et al. (13,14)
have designed novel types of zinc finger
chelators targeted against the E6 oncoprotein
of HPV-16.
A large series of polysulﬁdes such as 6 and
7 were prepared and tested in vitro for their
ability to disrupt the integrity of chelated zinc
ions present in the E6 HPV viral proteins. A
very large number of substitution patterns for
derivatives 6 and 7 have been investigated,
with R1, R2 moieties being simple alkyls,
cycloalkyls, aralkyls, hetaryls, and so on, or
R1R2N in a cyclic moiety (e.g., azacyclo-
propyl, morpholyl, phthalimido, piperazinyl,
etc.), as well as substituting such moieties
with halogens, acyl, and aryl/alkyloxycarbonyl
groups among others. The disulﬁdes (n = 2 in
6) were the most investigated and most active
such derivatives. The viability of HPV-
infected cells in the presence of the test com-
pounds 6 and 7 has also been determined (ex
vivo) (incubation with tetrazolium salt and
measuring of the optical absorption, with or
without test compound added). The most
active anti-HPV compounds of this type pro-
duced a release of zinc from E6 of at least
30%, reduced the binding of the E6 protein
to its coactivators E6AP or E6BP, and exhib-
ited selective cytotoxicity toward the
HPV-infected cells (14).
Thus, the disruption of a chelated metal
ion domain in a protein (in this particular
case a Zn(II) ion from a zinc ﬁnger protein)
may represent a fundamentally new approach
for the drug design of antiviral agents, not
only for obtaining new antiretroviral drugs,
but also for compounds targeted against
DNA viruses.
Anticancer Agents Targeting Cys
Residues of β -Tubulin and Carbonic
Anhydrases
Several widely used antitumor drugs (e.g., the
vinca alkaloids vincristine and vinblastine,
colchicine, and paclitaxel) exert their action
by binding to tubulin, a heterodimeric (αβ )
protein that is the key component of micro-
tubules and thus of the cytoskeleton, sustain-
ing the cell shape and facilitating the
movement and deposition of protein com-
plexes, organelles, and membrane vesicles
(2,15). Tubulins also play a crucial function
in cell division, being among the major con-
stituents of mitotic spindles, which are essen-
tial for chromosomal separation during
mitosis (15). Several β -tubulin isoforms are
known in humans (15–17). Some of the anti-
tumor drugs mentioned above, such as vin-
cristine, vinblastine, and colchicine, bind
reversibly to β -tubulin in disassembled tubu-
lin heterodimers, thereby interfering with
polymerization (15–17). Other agents alky-
late multiple Cys residues of β -tubulin and
affect microtubule formation, but generally
such compounds lacked any selectivity and
could not be used as drugs. Only recently,
two new classes of derivatives that speciﬁcally
bind to a Cys residue of β -tubulin have been
described and assayed for their antitumor
properties (15–17).
Medina and colleagues (15–17) reported
a series of perfluorophenylsulfonamide
derivatives 8–12, which strongly inhibited
the growth of a variety of tumors, including
Metals Toxicity • Cysteine-modifying drugs
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Hmultidrug-resistant cell lines. Compounds of
this type possessed GI50 values (growth-
inhibitory factor: the molarity of inhibitor
producing a 50% reduction of growth of the
tumor cells in vitro) in the low nanomolar
range for derivatives 8 and 11, and in the
range of 40–500 nM for the other deriva-
tives (15). Furthermore, the corresponding
derivatives possessing other halogens instead
of the ﬁve ﬂuorine atoms of 8 have also been
prepared, together with the corresponding
isomeric trifluoro- and tetrafluorosulfon-
amides, but all these derivatives were much
less active than the lead compound 8 (17).
This was subsequently shown to be due to
the mechanism of action of these com-
pounds, which covalently bind to Cys-239
of β -tubulin, by means of a nucleophilic
aromatic substitution reaction (17), in
which the most substitutionally active fluo-
rine atom of the antimitotic agent (i.e., the
fluorine in para with the sulfonamide moi-
ety) is displaced by the sulfur of Cys-239
residue of β -tubulin, leading to modiﬁcation
of the protein (Figure 1).
Scozzafava et al. (18,19) then reported a
series of alkyl/arylsulfonyl-N,N-dialkyldithio-
carbamates 13, obtained by reaction of
sodium N,N-dimethyldithiocarbamate or
N,N-diethyldithiocarbamate with alkyl/aryl-
sulfonyl halides. The reactivity of these deriv-
atives against Cys and glutathione has been
investigated to identify derivatives that might
label a Cys residue of β -tubulin, similarly to
compounds 8–12. Some of the most reactive
compounds against these thiol reagents also
showed strong GI50 values (in the low
micromolar range for some derivatives)
against several cancer cell lines: leukemia,
non–small-cell lung, ovarian, melanoma,
colon, central nervous system, renal,
prostate, and breast (Table 2). It has also
been proved (18,19) that such compounds
inhibit tubulin polymerization in vitro, prob-
ably by modiﬁcation of the same Cys residue
as in derivatives 8–12, investigated by
Medina and colleagues (15–17) (Figure 1).
At this point it is also worth mentioning
the very strong antitumor properties of some
sulfonamides of 14 and 15 (GI50 values in
the low nanomolar range) reported by our
group (20–22), which were initially designed
as carbonic anhydrase inhibitors. Although
the cellular target of these compounds is
presently unknown, it is probable that they
interfere with Cys residues of proteins
involved in oncogenesis, such as carbonic
anhydrase IX (20–22) or β -tubulin, because
of the presence of the reactive thiocarbamoyl-
sulfenylamino moieties in their molecules.
Conclusions
Cysteine, because of its unique properties
among the 20 natural amino acids— con-
nected with the presence of the thiol moiety
in its molecule—offers the possibility of
designing a host of therapeutic agents with
interesting pharmacological applications.
Such compounds interfere with one of
the speciﬁc properties of this amino acid pre-
sent in the target protein: a) the facile
participation of Cys in oxido-reduction
processes (leading to the formation of disul-
ﬁde bonds); b) its high afﬁnity for coordinat-
ing transition metal ions; or c) its high
nucleophilicity and propensity to be modiﬁed
(S-alkylated, S-acylated, S-sulfonylated, etc.).
Important applications have been
registered in the design of antiviral agents,
mainly targeted against HIV and HPV.
Agents that interact with the HIV-1 NC zinc
ﬁnger protein NCp7 were designed in such a
way as to produce zinc ejection from the zinc
ﬁnger, after oxidation of a Cys residue partici-
pating in coordination of the metal ion
within the zinc ﬁnger. Because the NC pro-
teins of all retroviruses, HIV included, are
transcription factors that select viral RNA
from cellular RNA for dimerization and
packaging, and also promote binding of the
essential transfer RNA primer to the primer
site, stimulate reverse transcription, and
protect the viral RNA from nucleases, these
proteins are essential for the viral life cycle,
and their mutation/modiﬁcation is not toler-
ated. Thus, this approach may evade the
drug resistance problems associated with
HAART, the classical anti-HIV therapy,
which targets the viral enzymes reverse tran-
scriptase and aspartic protease, both subject
to high rates of mutations that lead to emer-
gence of drug resistance. The same approach
of targeting viral zinc finger proteins has
been applied for the design of anti-HPV
agents, directed against the E6 oncoprotein
of HPV-16, which incorporates two
Cys–[X]2–Cys–[X]29–Cys–[X]2–Cys zinc ﬁn-
gers. The designed antivirals produced zinc
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Table 2. In vitro tumor growth inhibition data with compounds of the type shown in 13 (18,19).
RSO2SC(=)NEt2
13a-13e
GI50 (µM)a
13a 13b 13c 13d 13e
Tumor cell line o–HOOC–C6H4– o–O2N–C6H4– p–O2N–C6H4– p–H2N–C6H4– p–AcNH–C6H4–
Leukemia HL-60 (TB) 1.4 0.2 — >100 24
MOLT-4 —b 0.4 — 2 48
K-562 — 11 19 34 69
SR 3.6 0.3 0.1 3 0.01
CCRF-CEM 82 2.5 — >100 20
RPMI-8226 — 15 12 22 18
Non–small-cell A549/ATCC 6.5 3 1 7 0.2
lung cancer HOP-62 >100 20 32 33 18
HOP-92 >100 14 4 5 16
NCI-H226 >100 36 83 98 35
NCI-H522 1.2 0.08 0.02 1 <0.01
Colon cancer COLO-205 >100 28 19 >100 22
HCT-15 >100 34 52 >100 28
HT29 >100 14 22 — —
SW-620 >100 15 18 >100 16
HCC-2998 — 24 94 8 27
HCT-116 — 15 5 >100 15
KM12 — 12 11 22 13
Central nervous SF-268 >100 26 >100 >100 44
system cancer SF-295 >100 32 59 >100 28
SF-539 — 20 21 — —
SNB-75 >100 76 77 48 32
U251 >100 13 14 >100 15
Melanoma LOX IMVI >100 16 17 >100 14
M14 >100 11 15 63 15
MALME-3M 91 10 14 46 16
UACC-257 >100 17 24 >100 9
SK-MEL-28 >100 13 19 >100 15
SK-MEL-5 37 3 2 13 0.4
Ovarian cancer IGROV1 >100 0.5 — 5 12
OVCAR-4 >100 23 45 >100 22
OVCAR-3 >100 22 35 >100 31
OVCAR-8 >100 18 20 >100 15
Renal cancer 768–0 >100 19 16 3 17
ACHN >100 24 36 61 27
CAKI-1 >100 17 18 22 16
RXF 393 >100 15 16 22 11
UO-31 >100 13 21 80 20
TK-10 — 29 43 >100 48
SN12C — 18 27 >100 18
Prostate cancer PC-3 >100 54 — 90 —
DU-145 >100 19 27 >100 23
Breast cancer MCF7 >100 25 6 5 18
MDA-MB-231/ATCC >100 16 26 >100 20
NCI/ADR-RES — 30 48 >100 27
MDA-N >100 19 30 65 21
HS 578T — 29 >100 83 60
MDA-MB-435 — 18 23 >100 19
BT-549 — 26 36 >100 61
aMolarity of inhibitor producing a 50% inhibition of growth of the tumor cells after a 48-hr exposure to variable concentrations (10–4 to 10–8 M) of the test compound. bCompound has not
been tested for the inhibition of growth of these tumor lines.
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13ejection in the low micromolar concentration
and strongly inhibited viral growth in vitro,
leading to optimism regarding the possible
development of successful antiviral therapies
against this debilitating pathogenic agent.
Antitumor therapies that exploit the
modification of Cys residues present in pro-
teins critically involved in oncogenesis have
also been reported recently. Several agents
that target β -tubulin, such as pentaﬂuoroben-
zenesulfonamide derivatives or alkyl/arylsul-
fonyl-N,N-dialkyldithiocarbamates, were
shown to covalently bind to residue Cys-239
of β -tubulin, exerting in this way strong anti-
tumor properties against a wide range of
tumor cell lines (leukemia, non–small-cell
lung, ovarian, melanoma, colon, central ner-
vous system, renal, prostate, and breast can-
cer), including those with multidrug-resistant
phenotype. Thus, a nonclassical antitumor
agent that may evade the drug resistance
problems correlated with the clinically used
anticancer agents might be developed soon
from this class of pharmacological agents.
REFERENCES AND NOTES
1. Wedemeyer WJ, Welker E, Narayan M, Scheraga HA.
Disulfide bonds and protein folding. Biochemistry
39:4207–4216 (2000).
2. Scozzafava A, Mastrolorenzo A, Supuran CT. Agents that
target cysteine residues of biomolecules and their
therapeutic potential. Exp Opin Ther Patents 11:765–787
(2001).
3. Vallee B, Maret W. Metallothionein III. In: Metallothioneins
(Suzuki KT, Imura N, Kimura M, eds). Birkhauser:Basel,
1993;1–28.
4. Valee BL, Auld DS. Zinc coordination, function and
structure of zinc enzymes and other proteins.
Biochemistry 29:5647–5659 (1990).
5. Casini A, Scozzafava A, Mastrolorenzo A, Supuran CT.
Sulfonamides and sulfonylated derivatives as anticancer
agents. Curr Cancer Drug Targets 2:55–75 (2002).
6. Joly V, Yeny P. New trends in antiretroviral therapy of HIV
infection. Eur J Int Med 11:301–308 (2000).
7. Rice WG, Supko JG, Malspeis L, Buckheit RW, Clanton D,
Bu M. Inhibitors of HIV nucleocapsid protein zinc ﬁngers
as candidates for the treatment of AIDS. Science
270:1194–1197 (1995).
8. Ramboarina S, Moreller N, Fournie-Zaluski MC, Roques
BP. Structural investigation on the requirement of CCHH
zinc ﬁnger type nucleocapsid protein of human immunod-
eﬁciency virus 1. Biochemistry 38:9600–9607 (1999).
9. Huang M, Maynard A, Turpin JA, Graham L, Janini GM,
Covell DG, Rice WG. Anti-HIV agents that selectively tar-
get retroviral nucleocapsid protein zinc fingers without
affecting cellular zinc fingers. J Med Chem 41:1371–1381
(1998).
10. Turpin JA, Song Y, Inman JK, Huang M, Wallqvist A,
Maynard A. Synthesis and biological properties of novel
pyridinioalkanoyl thiolesters (PATE) as anti-HIV-1 agents
that target the viral nucleocapsid protein zinc fingers. J
Med Chem 42:67–86 (1999).
11. McGlennen RC. Human papillomavirus oncogenesis. Clin
Lab Med 20:383–406 (2000).
12. Grossman SR, Laimins LA. E6 protein of human papillo-
mavirus type 18 binds zinc. Oncogene 4:1089–1093 (1989).
13. Beerheide W, Bernard HU, Tan YJ, Ganesan A, Rice WG,
Ting AE. Potential drugs against cervical cancer: zinc-
ejecting inhibitors of human papillomavirus type 16 E6
oncoprotein. J Natl Cancer Inst 91:1211–1220 (1999).
14. Beerheide W, Sim MM, Tan YJ, Bernard HU, Ting AE.
Inactivation of the human papillomavirus-16 E6 oncopro-
tein by organic disulﬁdes. Bioorg Med Chem 8:2549–2560
(2000).
15. Medina JC, Shan B, Beckmann H, Farrell RP, Clark DL,
Learned RM. Novel antineoplastic agents with efficacy
against multidrug resistant tumor cells. Bioorg Med Chem
Lett 8:2653–2656 (1998).
16. Medina JC, Roche D, Shan B, Learned RM, Frankmoelle
WP, Clark DL. Novel halogenated sulfonamides inhibit the
growth of multidrug resistant MCF-7/ADR cancer cells.
Bioorg Med Chem Lett 9:1843–1846 (1999).
17. Shan B, Medina JC, Santha E, Frankmoelle WP, Chou TC,
Learned RM. Selective, covalent modiﬁcation of β -tubulin
residue Cys-239 by T138067, an antitumor agent with in
vivo efﬁcacy against multidrug-resistant tumors. Proc Natl
Acad Sci USA 96:5686–5691 (1999).
18. Scozzafava A, Mastrolorenzo A, Supuran CT. Arylsulfonyl-
N,N-diethyl-dithiocarbamates: a novel class of antitumor
agents. Bioorg Med Chem Lett 10:1887–1891 (2000).
19. Scozzafava A, Mastrolorenzo A, Supuran CT. Arylsulfonyl-
N,N-dialkyl-dithiocarbamates as tumor cell growth
inhibitors: novel agents targeting β -tubulin? J Enzyme
Inhib 16:55–63 (2001).
20. Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors:
synthesis of N-morpholylthiocarbonylsulfenylamino aro-
matic/heterocyclic sulfonamides and their interaction
with isozymes I, II and IV. Bioorg Med Chem Lett
10:1117–1120 (2000).
21. Supuran CT, Briganti F, Tilli S, Chegwidden WR, Scozzafava
A. Carbonic anhydrase inhibitors. Sulfonamides as anti-
tumor agents? Bioorg Med Chem 9:703–714 (2001).
22. Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors.
Curr Med Chem Imm Endoc Metab Agents 1:61–97 (2001).
806 VOLUME 110 | SUPPLEMENT 5 | OCTOBER 2002 • Environmental Health Perspectives
Metals Toxicity • Casini et al.